£10 Million Boost to Speed Up New Medicines for UK Patients
HM Treasury has splashed out £10 million to turbocharge the Medicines and Healthcare products Regulatory Agency (MHRA). The goal? To fast-track innovative medicines and medical tech straight to UK patients.
Faster Access to Cutting-Edge Treatments
The cash injection will help MHRA cut red tape and speed approval of breakthrough treatments over the next two years. Priority areas include cancer vaccines and AI-powered therapies for mental health. It’s all about getting the best new health tech into British hands, pronto.
Global Partnerships to Fast-Track Approvals
MHRA will launch an international recognition framework, teaming up with top regulators like the US FDA and Japan’s PMDA. This means trusted approvals abroad will help get products licensed faster in the UK, without compromising patient safety.
MHRA boss Dr June Raine said:
“We greatly welcome the £10 million funding announced by HM Treasury today, which will be used to fund our ongoing innovation work and to accelerate the development of ground-breaking global recognition routes, which will give UK patients faster access to the most cutting-edge medical products in the world.” “This cash injection will ensure that we have access to the best resources, talent, and infrastructure to deliver this ambitious vision for patients across the UK.”
Health Secretary Steve Barclay added:
“Technology is transforming our care for patients, delivering faster and more accurate diagnoses. This new funding will accelerate the delivery of cutting-edge treatments including cancer vaccines and new artificial intelligence technology that will make therapy more accessible to those who suffer from mental health conditions.” “It will also fast-track access to medical products that have been approved in other countries by trusted regulatory partners, ensuring we continue to provide the best, most innovative and safest treatments in the UK.”
MHRA: Leading the Way in Medical Innovation
The MHRA is a global powerhouse for medical regulation. Its Innovation Office, set up in 2013, guides healthcare innovators through complex rules. The agency’s international schemes like the Access Consortium and Project Orbis have already paved the way for groundbreaking medicines, including treatments for vision loss and cancer.
